ScholarIQanswers from OpenAlex & ORCID
Roy S. Herbst
ResearcherPublications, citations & collaboration network
Roy S. Herbst is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Roy S. Herbst have?
ScholarIQindexed works
Roy S. Herbst has 1,339 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Roy S. Herbst have?
ScholarIQcitation count
Roy S. Herbst has 94,314 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Roy S. Herbst?
ScholarIQh-index
Roy S. Herbst has an h-index of 135 in OpenAlex.
What is the i10-index of Roy S. Herbst?
ScholarIQi10-index
Roy S. Herbst has an i10-index of 488 in OpenAlex.
What is the ORCID of Roy S. Herbst?
ScholarIQorcid
The ORCID for Roy S. Herbst is on the source record.
What is the OpenAlex record for Roy S. Herbst?
ScholarIQopenalex
The OpenAlex for Roy S. Herbst is on the source record.
What are the most-cited papers on Roy S. Herbst?
ScholarIQmost cited works
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
Mark G. Kris, Ronald B. Natale, Roy S. Herbst, T. J. Lynch, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, H. Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael Wolf, Steven D. Averbuch, Judith Ochs, Andrea Kay
Lung Cancer
Roy S. Herbst, John V. Heymach, Scott M. Lippman
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Wei Zou, Alan Sandler, Ida Enquist, Kimberly M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Mark L. McCleland, Simonetta Mocci, Jacek Jassem, David R. Spigel